Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 283

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 283
---
 the following:

| 1. | A forward share split                                                                           
 at a ratio of a two and a half-for-one (2.5-for-1) of the Ordinary Shares and preferred shares. 
 As a result of the Split, for every one (1) share of share either issued and outstanding        
 will be granted two and a half (2.5) new Ordinary Shares or preferred shares, as applicable.    |

| 2. | Contingent upon                                                                                                                      
 the implementation of an initial public offering, the chairman of the Company’s board of directors will be eligible to: (i) annual   
 compensation of $250, to be paid on a quarterly basis; (ii) a grant of 283,532 options with an exercise price of NIS 0.01; and (iii) 
 at Qualified IPO (as defined below), a cash payment of $500. In addition,the holdings of the chairman of the Company’s board of      
 directors shall not be diluted any lower than 9.98% as a result of any IPO with a total proceeds of no less than $6,000 (“Qualified  
 IPO”).                                                                                                                               |

| 3. | Increase of authorized share capital from 3,000,000 to 22,500,000 
 shares.                                                           |

| 4. | Cancellation of the                                                  
 Company’s nominal value per each Ordinary Share and preferred share. |

On March 31, 2025, the Company and
the lenders of certain short-term loan agreements and convertible notes, signed an amendment to extend the maturity date of the loans
(see Note 5c, 5d and Note 6).

In April 2025, the Company entered
into bridge loan agreements (the “April 2025 Loans” or "April 2025 Loan Agreements"), pursuant to which the Company
obtained bridge loans from the lenders thereto including certain related parties, including the Company's chairman of the board of directors,
a member of the Company's board of directors, and a director nominee. The April 2025 Loans shall bear interest at 8% per annum until
maturity and the Company agreed to pay the lenders an additional risk premium equal to 50% of their respective loan amount.

The April 2025 Loan's maturity date
is the earlier of August 31, 2025, or the date of consummation of the QIPO. Furthermore, upon the occurrence of a QIPO, the April 202